Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock Holdings Lessened by NEOS Investment Management LLC

NEOS Investment Management LLC reduced its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 27.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 89,529 shares of the company's stock after selling 33,969 shares during the period. NEOS Investment Management LLC owned about 0.18% of Mineralys Therapeutics worth $1,102,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. JPMorgan Chase & Co. increased its holdings in Mineralys Therapeutics by 2,251.5% during the 4th quarter. JPMorgan Chase & Co. now owns 503,590 shares of the company's stock worth $6,199,000 after purchasing an additional 482,174 shares during the period. Jennison Associates LLC lifted its stake in Mineralys Therapeutics by 55.4% in the fourth quarter. Jennison Associates LLC now owns 1,082,006 shares of the company's stock worth $13,319,000 after acquiring an additional 385,726 shares during the period. Candriam S.C.A. purchased a new position in Mineralys Therapeutics during the 4th quarter valued at about $3,758,000. Franklin Resources Inc. raised its holdings in shares of Mineralys Therapeutics by 17.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,745,513 shares of the company's stock valued at $21,138,000 after purchasing an additional 262,922 shares in the last quarter. Finally, Caligan Partners LP lifted its position in shares of Mineralys Therapeutics by 31.6% in the 3rd quarter. Caligan Partners LP now owns 981,155 shares of the company's stock worth $11,882,000 after purchasing an additional 235,397 shares during the period. Hedge funds and other institutional investors own 84.46% of the company's stock.

Remove Ads

Insider Activity

In other Mineralys Therapeutics news, major shareholder Samsara Biocapital Gp, Llc bought 600,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average price of $13.50 per share, for a total transaction of $8,100,000.00. Following the completion of the purchase, the insider now directly owns 5,674,916 shares in the company, valued at $76,611,366. This trade represents a 11.82 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jon Congleton sold 18,333 shares of the business's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $9.06, for a total transaction of $166,096.98. Following the completion of the sale, the chief executive officer now directly owns 877,608 shares of the company's stock, valued at approximately $7,951,128.48. This trade represents a 2.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 33.24% of the company's stock.

Mineralys Therapeutics Trading Down 1.3 %

Mineralys Therapeutics stock traded down $0.18 during mid-day trading on Thursday, hitting $13.82. The company had a trading volume of 333,055 shares, compared to its average volume of 373,078. The company's fifty day moving average is $11.78 and its 200-day moving average is $12.26. Mineralys Therapeutics, Inc. has a 12-month low of $8.24 and a 12-month high of $18.38. The company has a market capitalization of $867.69 million, a price-to-earnings ratio of -3.80 and a beta of -0.39.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.98) earnings per share for the quarter, topping analysts' consensus estimates of ($1.00) by $0.02. As a group, sell-side analysts expect that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on MLYS shares. Guggenheim reiterated a "buy" rating on shares of Mineralys Therapeutics in a research note on Monday, February 24th. HC Wainwright raised their price objective on Mineralys Therapeutics from $30.00 to $42.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, The Goldman Sachs Group decreased their price objective on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating for the company in a research note on Thursday, February 13th.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.